Stock Analysis

European Growth Companies With High Insider Ownership February 2025

Published

As the European markets navigate cautious optimism amid geopolitical tensions and evolving trade policies, investors are keenly observing growth opportunities within the region. In this landscape, companies with high insider ownership often stand out as they may signal strong internal confidence and alignment of interests with shareholders, making them compelling candidates for those seeking growth potential.

Top 10 Growth Companies With High Insider Ownership In Europe

NameInsider OwnershipEarnings Growth
TF Bank (OM:TFBANK)15.6%20%
Elicera Therapeutics (OM:ELIC)27.8%97.2%
CD Projekt (WSE:CDR)29.7%39.4%
Bergen Carbon Solutions (OB:BCS)12%50.8%
Truecaller (OM:TRUE B)29.7%24.8%
XTPL (WSE:XTP)27.9%118%
BioArctic (OM:BIOA B)33.8%38.5%
Pharma Mar (BME:PHM)11.9%45.4%
Elliptic Laboratories (OB:ELABS)22.6%121.1%
MedinCell (ENXTPA:MEDCL)13.9%114.3%

Click here to see the full list of 214 stocks from our Fast Growing European Companies With High Insider Ownership screener.

Here we highlight a subset of our preferred stocks from the screener.

Esprinet (BIT:PRT)

Simply Wall St Growth Rating: ★★★★☆☆

Overview: Esprinet S.p.A. is involved in the wholesale distribution of IT products and consumer electronics across Italy, Spain, Portugal, and other parts of Europe, with a market cap of €244.74 million.

Operations: Esprinet's revenue is derived from the wholesale distribution of IT products and consumer electronics throughout Italy, Spain, Portugal, and other European regions.

Insider Ownership: 13.4%

Earnings Growth Forecast: 22.1% p.a.

Esprinet is positioned for significant earnings growth at 22.1% annually, outpacing the Italian market's average. Despite trading 34.7% below estimated fair value and being a good relative value compared to peers, its Return on Equity is forecasted to be low at 7.9%. The company recently became profitable but faces challenges with interest coverage by earnings. Analysts agree on a potential stock price increase of 32%, indicating optimism about future performance.

BIT:PRT Earnings and Revenue Growth as at Feb 2025

Admicom Oyj (HLSE:ADMCM)

Simply Wall St Growth Rating: ★★★★★☆

Overview: Admicom Oyj provides cloud-based software and business process automation solutions in Finland, with a market cap of €269.27 million.

Operations: The company's revenue is primarily derived from its Software & Programming segment, which amounts to €35.57 million.

Insider Ownership: 21.9%

Earnings Growth Forecast: 22% p.a.

Admicom Oyj, with strong insider ownership, is forecasted for significant earnings growth of 22% annually, surpassing the Finnish market average. Despite a slight dip in net income to €5.87 million for 2024, the company remains undervalued by 27.7% relative to its fair value estimate. Revenue growth is projected at 10.7%, outpacing the local market's rate. Admicom's Return on Equity is expected to reach a high of 29.6% in three years.

HLSE:ADMCM Ownership Breakdown as at Feb 2025

Brockhaus Technologies (XTRA:BKHT)

Simply Wall St Growth Rating: ★★★★☆☆

Overview: Brockhaus Technologies AG is a private equity firm with a market cap of €253.88 million.

Operations: The company's revenue is primarily derived from its Security Technologies segment, which accounts for €35.20 million, and its HR Benefit & Mobility Platform segment, contributing €184.13 million.

Insider Ownership: 26.6%

Earnings Growth Forecast: 114.4% p.a.

Brockhaus Technologies is poised for substantial growth, with earnings expected to rise 114.4% annually, outpacing the German market's average. Despite trading at 71.2% below its estimated fair value, the company faces a low forecasted Return on Equity of 4.3% in three years. Revenue is projected to grow at 12.6% per year, slower than high-growth benchmarks but faster than the broader market's rate of 5.8%.

XTRA:BKHT Earnings and Revenue Growth as at Feb 2025

Seize The Opportunity

Contemplating Other Strategies?

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.The analysis only considers stock directly held by insiders. It does not include indirectly owned stock through other vehicles such as corporate and/or trust entities. All forecast revenue and earnings growth rates quoted are in terms of annualised (per annum) growth rates over 1-3 years.

Valuation is complex, but we're here to simplify it.

Discover if Esprinet might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.

Access Free Analysis

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com